ENA Respiratory has dosed the first participants in Part B of its Phase IIa community study of INNA-051, a virus-agnostic, dry powder nasal spray. INNA-051 is designed to prime the natural antiviral host defences in the nose where common respiratory viruses like rhinovirus, flu, RSV and coronaviruses… Read More
ENA Respiratory and the University of Maryland have announced plans to partner on a Phase II study of INNA-051 for the prevention of illness due to viral respiratory infections. Dr Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine’s Center for Vaccine and… Read More
Australian clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the US Department of Defense (DOD) to support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator for the prevention of complications associated with respiratory viral infections in at-risk populations. … Read More
